Kali Inc (OP: KALY )
0.0016 USD UNCHANGED Official Closing Price Updated: 3:59 PM EDT, Apr 16, 2021 Add to My Watchlist
Stories about Kali Inc
The Week In Cannabis: Davos, Aphria's Funding, Moves In Alaska, New York And Vermont
January 26, 2020
As the World Economic Forum unfolded in Davos, Switzerland, world leaders gathered to discuss, among other important topics, cannabis, ...
Stocks That Hit 52-Week Lows On Wednesday
November 27, 2019
Wednesday's morning session saw 88 companies set new 52-week lows. Noteworthy Highlights: ANZ Bank (OTC: ANEWF) was the ...
The Week Ahead In Cannabis: NCIA's 3rd California Cannabis Business Conference, A New Service From Driven Deliveries And More
October 07, 2019
Here's a short overview of some of the main business updates and events in the cannabis industry is looking forward to this ...
The Week Ahead In Cannabis: Utah Holds Special Session On Legalization, Supreme Cannabis Earnings And More
September 16, 2019
Cannabis investors will have their hands full this week, as a number of corporate and political updates are scheduled. Benzinga has ...
The next five days will still be full of news surrounding the cannabis space. We have compiled a list of main things that cannabis ...
BRIEF-Kalytera Announces Issuance Of Patent Covering The Use Of CBD For The Treatment Of Severe And Refractory Graft Versus Host Disease
April 19, 2018
* KALYTERA ANNOUNCES ISSUANCE OF PATENT COVERING THE USE OF CBD FOR THE TREATMENT OF SEVERE AND REFRACTORY GRAFT VERSUS HOST DISEASE
* DETERMINED INVESTMENTS OF TIME, RESOURCES IN THESE PROGRAMS NOT APPROPRIATE GIVEN OTHER OPPORTUNITIES IN DEVELOPMENT PIPELINE
BRIEF-Kalytera Initiates Program To Develop A Novel Cannabinoid-Based Compound For Treatment Of Acute And Chronic Pain
March 20, 2018
* KALYTERA INITIATES PROGRAM TO DEVELOP A NOVEL CANNABINOID-BASED COMPOUND FOR TREATMENT OF ACUTE AND CHRONIC PAIN
BRIEF-Kalytera Therapeutics Says ?Results Of Phase 2 Clinical Study In Prevention Of Graft Versus Host Disease? Are Expected By Q3 2018
December 07, 2017
* KALYTERA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PREVENTION OF GRAFT VERSUS HOST DISEASE AND AGREEMENT WITH THE SALZMAN GROUP OF ISRAEL TO MANAGE AND PARTIALLY FUND THE STUDY TO BE LED BY A...
BRIEF-Kalytera Therapeutics names Robert Farrell CEO
October 10, 2017
* Kalytera Therapeutics, Inc. announces Robert Farrell, J.D. as CEO; additional board and management changes
* Kalytera submits phase 2 study protocol to IRBS for cannabidiol in the prevention of graft versus host disease
* Kalytera Therapeutics Inc - Robert Farrell, J.D., president and cfo of Kalytera, will assume role of interim chief executive officer
BRIEF-Kalytera Therapeutics Q1 loss per share $0.02
May 31, 2017
* Working capital totaled $1.8 million, including cash and cash equivalents of $3.1 million, as of March 31, 2017 Source text for Eikon: Further company coverage:
* Kalytera Therapeutics Inc - announced appointment of Ronald P. Erickson as interim chairman of its board of directors
* Kalytera Therapeutics appoints Pini Ben-Elazar to board of directors Source text for Eikon: Further company coverage:
* Kali Inc engages Caprock Research to initiate independent analyst coverage on company roll-up in $5 billion fragmented and underserved Marina management sector Source text for Eikon: Further company...